- Stocks
- Pharma & Healthcare
- Natural Capsules
Natural Capsules share price
NSE: NATCAPSUQPharma & HealthcareDrug Manufacturers - Specialty & Generic
Natural Capsules at a glance
Natural Capsules (NSE: NATCAPSUQ) closed at ₹150.40 on 22 Oct 2026, down 2.21% on the day. With a market capitalisation of ₹157 Cr, it ranks 2408th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was −7.7% in FY26. Over the past year the share price has fallen 34.6%. Its 52-week range is ₹136.36 (27 Mar 2026) to ₹234.00 (4 Sep 2026); the last close is 35.7% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹58 Cr (+30.0% year on year) and net profit −₹5 Cr (−1,057.7%), on a consolidated basis. Promoters held 50.92% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹157 CrRank 2408 on NSE
- Price to book
- 0.68×FY26
- EPS (TTM)
- −₹23.86to Q4 FY26
- ROE
- −7.7%FY26
- ROCE
- −5.8%FY26
- Debt to equity
- 0.52FY26
- Net profit margin
- −13.2%FY26
- Book value / share
- ₹213.39FY26
- 52-week high
- ₹234.004 Sep 2026
- 52-week low
- ₹136.3627 Mar 2026
- 1-year return
- −34.6%
- RSI (14-day)
- 36.5
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −2.21% | −4.7% | −9.9% | +5.3% | −34.6% |
Natural Capsules quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹39 Cr | ₹41 Cr | ₹44 Cr | ₹45 Cr | ₹45 Cr | ₹46 Cr | ₹38 Cr | ₹58 Cr |
| Revenue YoY | +3.9% | +9.9% | +9.6% | +11.8% | +15.4% | +11.1% | −13.9% | +30.0% |
| Net profit | ₹1 Cr | −₹1 Cr | ₹0 Cr | ₹1 Cr | −₹6 Cr | −₹7 Cr | −₹7 Cr | −₹5 Cr |
| Net profit YoY | −67.0% | −139.1% | −90.9% | −46.4% | −1,030.0% | — | −6,572.7% | −1,057.7% |
| Net margin | 1.5% | −1.5% | 0.3% | 1.2% | −12.3% | −15.3% | −18.9% | −8.5% |
| EPS | ₹0.65 | −₹0.60 | ₹0.10 | ₹0.13 | −₹5.40 | −₹6.76 | −₹6.88 | −₹4.82 |
Natural Capsules financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹80 Cr | ₹135 Cr | ₹172 Cr | ₹155 Cr | ₹169 Cr | — |
| Operating profit | ₹7 Cr | ₹19 Cr | ₹25 Cr | ₹8 Cr | ₹3 Cr | — |
| Net profit | ₹7 Cr | ₹14 Cr | ₹18 Cr | ₹6 Cr | ₹1 Cr | — |
| EPS (₹) | ₹11.00 | ₹20.00 | ₹20.00 | ₹6.00 | ₹0.00 | — |
| Cash from operations | ₹13 Cr | ₹1 Cr | ₹17 Cr | −₹8 Cr | ₹27 Cr | — |
| Total debt | ₹0 Cr | ₹33 Cr | ₹70 Cr | ₹68 Cr | ₹56 Cr | ₹55 Cr |
| Shareholders' equity | ₹62 Cr | ₹83 Cr | ₹123 Cr | ₹204 Cr | ₹233 Cr | ₹222 Cr |
Natural Capsules shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 51.21% | 51.26% | 51.26% | 51.26% | 51.04% | 50.92% |
| Non-institutions | 48.79% | 48.74% | 48.74% | 48.74% | 48.96% | 49.08% |
Natural Capsules vs peers
The listed Pharma & Healthcare companies nearest to Natural Capsules by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| MEDICOMedico Remedies | ₹20.71 | −0.43% | −57.5% | ₹172 Cr | 13.1 | — |
| MADHAVBAUGVaidya Sane Ayu | ₹161.10 | −4.11% | −43.1% | ₹169 Cr | — | — |
| TAKETake Solutions | ₹11.23 | −1.23% | −36.8% | ₹166 Cr | 38.7 | — |
| PANCHSHEELPanchsheel Org | — | — | — | ₹159 Cr | — | — |
| NATCAPSUQNatural Capsules | ₹150.40 | −2.21% | −34.6% | ₹157 Cr | — | — |
| AUROLABAuro Labs | — | — | — | ₹156 Cr | — | — |
| KIMIABLKimia Bio | — | — | — | ₹152 Cr | — | — |
Ask anything about Natural Capsules
Pivot answers on the live chart with evidence you can check, and tests strategies against NATCAPSUQ's own history. Try: “Why has NATCAPSUQ moved over the last three months?” · “Backtest a 50-day moving-average crossover on NATCAPSUQ over five years” · “Compare NATCAPSUQ with MEDICO on margins and valuation”
Frequently asked questions about Natural Capsules
What is the share price of Natural Capsules today?
Natural Capsules (NSE: NATCAPSUQ) last closed at ₹150.40 on 22 Oct 2026. Its 52-week high is ₹234.00 and its 52-week low is ₹136.36.
What is the market cap of Natural Capsules?
Natural Capsules' market capitalisation is ₹157 Cr (₹157 Cr) at the 22 Oct 2026 close, ranking 2408th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Natural Capsules?
Return on equity was −7.7% in FY26 and return on capital employed was −5.8% in FY26 (consolidated figures).
Is Natural Capsules a debt-free company?
No. Natural Capsules' debt-to-equity ratio was 0.52 in FY26, with total debt of ₹55 Cr.
What were Natural Capsules' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Natural Capsules reported revenue of ₹58 Cr, +30.0% year on year, and net profit of −₹5 Cr, −1,057.7% year on year.
How has Natural Capsules stock performed over the last year?
Natural Capsules' share price has fallen 34.6% over the past year, +5.3% over three months and −9.9% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Natural Capsules?
As of 30 Jun 2026: promoters 50.92%, non-institutions 49.08%.
Who are Natural Capsules' competitors?
The listed Pharma & Healthcare companies closest to Natural Capsules by market cap are Medico Remedies, Vaidya Sane Ayu, Take Solutions, Panchsheel Org, Auro Labs and Kimia Bio.
Is Natural Capsules a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Natural Capsules' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on NATCAPSUQ against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with N · all NSE stocks · this page as text